Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study

Table 3 Comparison between type-1 and type-2 hepatorenal syndrome

	Type-1 HRS(n = 15)	Type-2 HRS(n = 18)	P value
Age (yr)	63.3 ± 8.5	68.2 ± 10.2	0.150
Sex
Male	8 (53.3)	9 (50.0)	0.800
Female	7 (46.7)	9 (50.0)
Etiology
HCV	9 (60.0)	14 (77.8)	0.500
Alcohol	3 (20.0)	2 (11.1)
Cryptogenic	3 (20.0)	2 (11.1)
Child-Pugh
B	8 (53.3)	10 (55.6)	0.900
C	7 (46.7)	8 (44.4)
Diabetes mellitus	5 (33.3)	8 (44.4)	0.500
Hepatocellular carcinoma	6 (40.0)	6 (33.3)	0.700
Portal vein thrombosis	4 (26.7)	3 (16.7)	0.500
Platelets (× 103/mmc)	108.7 ± 96.6	101.6 ± 7711	0.800
BUN (mg/dL)	152 ± 73.4	139.5 ± 51.7	0.500
Creatinine (mg/dL)	3.95 ± 1.13	2.75 ± 0.71	0.001
Creatinine clearance	8 (5.2-17)	24.5 (15-26)	0.030
Sodium (mEq/L)	130.8 ± 4.24	130.7 ± 6.47	0.900
Potassium (mEq/L)	4.9 ± 0.96	4.97 ± 0.78	0.800
Urinary sodium (mEq/L)	11 (2.0-17.7)	6 (2-11)	0.700
Urinary potassium (mEq/L)	19 (7.2-38.2)	16 (11-27.75)	0.900
Total bilirubin (mg/dL)	6.37 (1.6-27.1)	2.62 (1.3-13.2)	0.200
INR	1.51 (1.3-2.2)	1.29 (1.18-1.6)	0.040
MELD score	31 (26-33)	23 (20-26)	0.010

Data are expressed as absolute mean ± SD or median (IQR). IQR: Interquartile range; BUN: Blood urea nitrogen; INR: International normalized ratio; MELD: Model for End stage liver disease.